Y Intercept Hong Kong Ltd Takes $1.19 Million Position in Celldex Therapeutics, Inc. $CLDX

Y Intercept Hong Kong Ltd bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 58,398 shares of the biopharmaceutical company’s stock, valued at approximately $1,188,000. Y Intercept Hong Kong Ltd owned about 0.09% of Celldex Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. acquired a new position in Celldex Therapeutics during the second quarter worth $861,000. Nisa Investment Advisors LLC increased its holdings in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 881 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Celldex Therapeutics by 7.0% in the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 844 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Celldex Therapeutics by 62.1% in the second quarter. TD Asset Management Inc now owns 127,878 shares of the biopharmaceutical company’s stock valued at $2,602,000 after purchasing an additional 49,000 shares during the last quarter. Finally, Sovran Advisors LLC bought a new stake in shares of Celldex Therapeutics in the second quarter valued at about $842,000.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CLDX. Barclays assumed coverage on shares of Celldex Therapeutics in a research report on Monday, October 13th. They issued an “underweight” rating and a $25.00 target price for the company. HC Wainwright dropped their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating for the company in a report on Wednesday, August 20th. Citigroup dropped their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating for the company in a research note on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.20.

Celldex Therapeutics Stock Down 7.4%

Shares of CLDX opened at $24.75 on Tuesday. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $29.05. The business’s fifty day moving average is $25.32 and its 200 day moving average is $22.62. The stock has a market cap of $1.64 billion, a P/E ratio of -8.22 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. On average, analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.